2933.99.14 | 00 | 5-Amino-4-chloro- α-phenyl-3- pyridazinone | kg | 6.5% | Free (A,AU,BH,CA, CL,E,IL,J,JO, MA,MX, P,SG) | 15.4¢/kg + 40.5% |
2933.99.55 | | Analgesics, antipyretics and nonhormonal anti-inflammatory agents | | 6.5% | Free (A*,AU,BH, CA,CL,E,IL,J,JO, K,MA,MX, P,SG) | 15.4¢/kg + 47.5% |
2933.99.65 | 00 | Anticonvulsants, hypnotics and sedatives | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P,SG) | 15.4¢/kg + 48.5% |
2933.99.79 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,L,MA,MX, P) 2.9% (SG) | 15.4¢/kg + 52% |
2933.99.82 | 10 | Benzotriazole (CAS No. 95-14-7) | kg | | | |
2933.99.82 | 20 | Tolyltriazole (CAS No. 29385-43-1) | kg | | | |
2933.99.85 | 00 | 3-Amino-1,2,4-triazole | kg | 3.7% | Free (A,AU,BH,CA, CL,E,IL,J,JO, MA,MX,P,SG) | 25% |
2934 | | Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds: | | | | |
2934.10 | | Compounds containing an unfused thiazole ring (whether or not hydrogenated) in the structure: | | | | |
2934.10.10 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P) 2.9% (SG) | 15.4¢/kg + 52% |
2934.10.70 | 00 | 4,5-Dichloro-2-n-octyl-4-isothiazolin-3-one; Ethyl 2-(2-aminothiazol-4-yl)-2- hydroxyiminoacetate; Ethyl 2-(2-aminothiazol-4-yl)-2- methoxyiminoacetate; 2-Methyl-4-isothiazolin- 3-one; 2-n-Octyl-4-isothiazolin-3-one; and Thiothiamine hydrochloride | kg | Free | | 30.5% |
2934.20 | | Compounds containing in the structure a benzothiazole ring-system (whether or not hydrogenated), not further fused: | | | | |
2934.20.25 | 00 | 2-Amino-5,6-dichlorobenzothiazole; 2-(4-Aminophenyl)-6-methylbenzothiazole-7- sulfonic acid; 2-Amino-6-nitrobenzothiazole; and N,N-Dicyclohexyl-2-benzothiazolesulfenamide | kg | Free | | 15.4¢/kg + 52% |
2934.20.30 | 00 | 2-Amino-6-methoxybenzothiazole; 2-Amino-6-methylbenzothiazole; 6-Ethoxy-2-benzothiazolethiol; 3-Methylbenzothiazole-2-hydrazone; and Primuline base | kg | 5.8% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,L,MA,MX, P,SG) | 15.4¢/kg + 39.5% |
2934.20.40 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,L,MA,MX, P) 2.9% (SG) | 15.4¢/kg + 52% |
2934.30 | | Compounds containing in the structure a phenothiazine ring-system (whether or not hydrogenated), not further fused: | | | | |
2934.30.12 | 00 | 2-(Trifluoromethyl)phenothiazine | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,MA,MX, P,SG) | 15.4¢/kg + 45% |
2934.30.18 | 00 | Ethyl (1H-phenothiazin-2,4,1)carbamate | kg | Free | | 15.4¢/kg + 52% |
2934.30.43 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P) 2.9% (SG) | 15.4¢/kg + 52% |
2934.91.00 | 00 | Aminorex (INN), brotizolam (INN), clotiazepam (INN), cloxazolam (INN), dextromoramide (INN), haloxazolam (INN), ketazolam (INN), mesocarb (INN), oxazolam (INN), pemoline (INN), phendimetrazine (INN), phenmetrazine (INN) and sufentanil (INN); salts thereof | kg | Free | | 15.4¢/kg + 52% |
2934.99.01 | 00 | Mycophenolate mofetil | kg | Free | | 15.4¢/kg + 45% |
2934.99.03 | 00 | 2-Acetylbenzo(b)thiophene; 3-Methylene-7-(2-phenoxyacetamido)- cephan-4-carboxylic acid, p-nitrobenzyl ester, 1-oxide; and Naphth[1,2-d]-[1,2,3]-oxadiazole-5-sulfonic acid and its sodium salt | kg | Free | | 15.4¢/kg + 52% |
2934.99.05 | 00 | 5-Amino-3-phenyl-1,2,4-thiadiazole (3-Phenyl-5-amino-1,2,4-thiadiazole); 2-Hydroxybenzoxazole (Benzoxazolone); 4-Phenylmorpholine; 1,9-Thianthrenedicarboxylic acid; and Thioxanthene-9-one (Thioxanthone) | kg | 5.8% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,MA,MX, P,SG) | 15.4¢/kg + 39.5% |
2934.99.07 | 00 | Ethyl 2-[4-[(6-chloro-2-benzoxazolyl)oxy]- phenoxy]propanoate (Fenoxaprop-ethyl) | kg | Free | | 15.4¢/kg + 48.5% |
2934.99.39 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,L,MA,MX, P) 2.9% (SG) | 15.4¢/kg + 52% |